Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · Real-Time Price · USD
128.60
+0.06 (0.05%)
Feb 21, 2025, 4:00 PM EST - Market closed
Intra-Cellular Therapies Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 680.85 | 464.37 | 250.31 | 83.8 | 22.81 | Upgrade
|
| Revenue Growth (YoY) | 46.62% | 85.51% | 198.69% | 267.35% | 37537.14% | Upgrade
|
| Cost of Revenue | 56.96 | 213.89 | 155.16 | 96.88 | 67.68 | Upgrade
|
| Gross Profit | 623.89 | 250.48 | 95.16 | -13.08 | -44.86 | Upgrade
|
| Selling, General & Admin | 504.49 | 409.86 | 358.78 | 272.61 | 186.36 | Upgrade
|
| Research & Development | 236.12 | - | - | - | - | Upgrade
|
| Operating Expenses | 740.61 | 409.86 | 358.78 | 272.61 | 186.36 | Upgrade
|
| Operating Income | -116.72 | -159.38 | -263.63 | -285.69 | -231.23 | Upgrade
|
| Interest & Investment Income | - | 20.34 | 7.38 | 1.57 | 4.24 | Upgrade
|
| Other Non Operating Income (Expenses) | 42.52 | - | - | - | - | Upgrade
|
| Pretax Income | -74.2 | -139.04 | -256.25 | -284.12 | -226.99 | Upgrade
|
| Income Tax Expense | 0.47 | 0.64 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Net Income | -74.68 | -139.67 | -256.26 | -284.13 | -227.01 | Upgrade
|
| Net Income to Common | -74.68 | -139.67 | -256.26 | -284.13 | -227.01 | Upgrade
|
| Shares Outstanding (Basic) | 103 | 96 | 94 | 81 | 70 | Upgrade
|
| Shares Outstanding (Diluted) | 103 | 96 | 94 | 81 | 70 | Upgrade
|
| Shares Change (YoY) | 7.56% | 1.95% | 15.74% | 15.47% | 27.50% | Upgrade
|
| EPS (Basic) | -0.72 | -1.46 | -2.72 | -3.50 | -3.23 | Upgrade
|
| EPS (Diluted) | -0.72 | -1.46 | -2.72 | -3.50 | -3.23 | Upgrade
|
| Free Cash Flow | - | -124.47 | -270.96 | -259.87 | -230.34 | Upgrade
|
| Free Cash Flow Per Share | - | -1.30 | -2.88 | -3.20 | -3.27 | Upgrade
|
| Gross Margin | 91.63% | 53.94% | 38.01% | -15.60% | -196.66% | Upgrade
|
| Operating Margin | -17.14% | -34.32% | -105.32% | -340.90% | -1013.58% | Upgrade
|
| Profit Margin | -10.97% | -30.08% | -102.37% | -339.04% | -995.07% | Upgrade
|
| Free Cash Flow Margin | - | -26.80% | -108.25% | -310.10% | -1009.69% | Upgrade
|
| EBITDA | -116.19 | -158.85 | -262.97 | -285.16 | -230.7 | Upgrade
|
| EBITDA Margin | -17.07% | -34.21% | -105.06% | - | - | Upgrade
|
| D&A For EBITDA | 0.53 | 0.53 | 0.66 | 0.53 | 0.53 | Upgrade
|
| EBIT | -116.72 | -159.38 | -263.63 | -285.69 | -231.23 | Upgrade
|
| EBIT Margin | -17.14% | -34.32% | -105.32% | - | - | Upgrade
|
| Revenue as Reported | 680.85 | 464.37 | 250.31 | 83.8 | 22.81 | Upgrade
|
| Advertising Expenses | - | 92.2 | 85.8 | 82.5 | 36.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.